Active mutations of the EGFR gene have been proved to predict the activity of EGFR-TKI. The most common mutations are the exon 19 deletion and exon 21 point mutation, both of which are sensitive to EGFR-TKI. However, rare EGFR mutations or complex mutations still exist, and data of which are scarce and controversial. Their response to EGFR-TKI remains uncertain. We presented a patient diagnosed with stage IV lung adenocarcinoma who was found to have the EGFR mutation in exon 19 (L747P) before any treatment. The disease progressed 2 months after the chemotherapy containing cisplatin and pemetrexed, and erlotinib was administered, but there was no response found. This EGFR-TKI naïve patient failed to achieve the desired effect with the therapy of EGFR-TKI. L747P may be associated with primary resistance to EGFR-TKI in this case.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4958842 | PMC |
| http://dx.doi.org/10.21037/jtd.2016.05.95 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The treatment of patients with non-small cell lung cancer carrying uncommon mutations, mutations, or brain metastases: a systematic review of pre-clinical and clinical findings for dacomitinib.
Transl Cancer Res
August 2023
Department of Medical Oncology, West China Hospital of Sichuan University, Chengdu, China.
Background: Accumulating evidence has shown that dacomitinib has potential activities for patients with non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor () mutations, human epidermal growth factor receptor 2 () mutations, or central nervous system (CNS) metastases.
Methods: This study aimed to give a systematic review on its potential applications in the above settings by searching MEDLINE/PubMed, Embase, Cochrane Library, American Society of Clinical Oncology.org, European Society for Medical Oncology.
Atypical Droplet Digital Polymerase Chain Reaction Patterns That Indicate Uncommon but Clinically Actionable EGFR Mutations in Lung Cancer.
Arch Pathol Lab Med
May 2024
From the Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (Lechner, Rai, Rojas-Rudilla, Sholl, Dong).
Article Synopsis
- ddPCR is an effective tool for detecting both common and uncommon pathogenic EGFR mutations in non-small cell lung cancer, which can influence treatment decisions.
- A study of 1134 lung cancer cases found that 22.5% had pathogenic EGFR mutations, with many falling into common categories, but also identified 9.8% with atypical mutations detectable through ddPCR.
- Recognizing unusual patterns in ddPCR results can guide additional testing and improve targeted therapy options for patients with lung cancer.
Afatinib treatment in a lung adenocarcinoma patient harboring a rare EGFR L747P mutation.
J Cancer Res Ther
September 2022
Department of Pulmonary and Critical Care Medicine, Cancer Center, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
Classical activating alterations including exon 19 deletions and exon 21 L858R point mutations comprise the majority of epidermal growth factor receptor (EGFR) changes in non-small cell lung cancer. Patients with these exhibit excellent clinical responses to EGFR tyrosine kinase inhibitors (TKIs). However, rare alterations including point mutations, deletions, and insertions occur and are associated with poorer responses to EGFR TKIs.
View Article and Find Full Text PDFCase Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases.
Front Oncol
August 2022
Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, China.
Due to the low incidence of rare EGFR mutation, its response to EGFR-TKI has not been fully investigated. L747P is a rare EGFR mutation in EGFR exon 19. Previous case reports showed that patients with EGFR L747P mutation responded to afatinib treatment.
View Article and Find Full Text PDFThe Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors.
Front Oncol
February 2022
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Objectives: The uncommon p.L747P mutation in epidermal growth factor receptor (EGFR) exon 19 reveals to alter the response to tyrosine kinase inhibitors (TKIs) in patients diagnosed with advanced non-small cell lung cancer (NSCLC). However, the underlying mechanism is still not clear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!